Cargando…

Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride accumulation in the hepatocytes in the absence of alcohol overconsumption, commonly associated with insulin resistance and obesity. Both NAFLD and type 2 diabetes (T2D) are characterized by an altered microbiota c...

Descripción completa

Detalles Bibliográficos
Autores principales: Motta, Benedetta M., Grander, Christoph, Gögele, Martin, Foco, Luisa, Vukovic, Vladimir, Melotti, Roberto, Fuchsberger, Christian, De Grandi, Alessandro, Cantaloni, Chiara, Picard, Anne, Mascalzoni, Deborah, Rossini, Alessandra, Pattaro, Cristian, Tilg, Herbert, Pramstaller, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891972/
https://www.ncbi.nlm.nih.gov/pubmed/31801616
http://dx.doi.org/10.1186/s12967-019-02130-z
_version_ 1783475936095633408
author Motta, Benedetta M.
Grander, Christoph
Gögele, Martin
Foco, Luisa
Vukovic, Vladimir
Melotti, Roberto
Fuchsberger, Christian
De Grandi, Alessandro
Cantaloni, Chiara
Picard, Anne
Mascalzoni, Deborah
Rossini, Alessandra
Pattaro, Cristian
Tilg, Herbert
Pramstaller, Peter P.
author_facet Motta, Benedetta M.
Grander, Christoph
Gögele, Martin
Foco, Luisa
Vukovic, Vladimir
Melotti, Roberto
Fuchsberger, Christian
De Grandi, Alessandro
Cantaloni, Chiara
Picard, Anne
Mascalzoni, Deborah
Rossini, Alessandra
Pattaro, Cristian
Tilg, Herbert
Pramstaller, Peter P.
author_sort Motta, Benedetta M.
collection PubMed
description BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride accumulation in the hepatocytes in the absence of alcohol overconsumption, commonly associated with insulin resistance and obesity. Both NAFLD and type 2 diabetes (T2D) are characterized by an altered microbiota composition, however the role of the microbiota in NAFLD and T2D is not well understood. To assess the relationship between alteration in the microbiota and NAFLD while dissecting the role of T2D, we established a nested study on T2D and non-T2D individuals within the Cooperative Health Research In South Tyrol (CHRIS) study, called the CHRIS-NAFLD study. Here, we present the study protocol along with baseline and follow-up characteristics of study participants. METHODS: Among the first 4979 CHRIS study participants, 227 individuals with T2D were identified and recalled, along with 227 age- and sex-matched non-T2D individuals. Participants underwent ultrasound and transient elastography examination to evaluate the presence of hepatic steatosis and liver stiffness. Additionally, sampling of saliva and faeces, biochemical measurements and clinical interviews were carried out. RESULTS: We recruited 173 T2D and 183 non-T2D participants (78% overall response rate). Hepatic steatosis was more common in T2D (63.7%) than non-T2D (36.3%) participants. T2D participants also had higher levels of liver stiffness (median 4.8 kPa, interquartile range (IQR) 3.7, 5.9) than non-T2D participants (median 3.9 kPa, IQR 3.3, 5.1). The non-invasive scoring systems like the NAFLD fibrosis score (NFS) suggests an increased liver fibrosis in T2D (mean − 0.55, standard deviation, SD, 1.30) than non-T2D participants (mean − 1.30, SD, 1.17). DISCUSSION: Given the comprehensive biochemical and clinical characterization of study participants, once the bioinformatics classification of the microbiota will be completed, the CHRIS-NAFLD study will become a useful resource to further our understanding of the relationship between microbiota, T2D and NAFLD.
format Online
Article
Text
id pubmed-6891972
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68919722019-12-11 Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study Motta, Benedetta M. Grander, Christoph Gögele, Martin Foco, Luisa Vukovic, Vladimir Melotti, Roberto Fuchsberger, Christian De Grandi, Alessandro Cantaloni, Chiara Picard, Anne Mascalzoni, Deborah Rossini, Alessandra Pattaro, Cristian Tilg, Herbert Pramstaller, Peter P. J Transl Med Protocol BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride accumulation in the hepatocytes in the absence of alcohol overconsumption, commonly associated with insulin resistance and obesity. Both NAFLD and type 2 diabetes (T2D) are characterized by an altered microbiota composition, however the role of the microbiota in NAFLD and T2D is not well understood. To assess the relationship between alteration in the microbiota and NAFLD while dissecting the role of T2D, we established a nested study on T2D and non-T2D individuals within the Cooperative Health Research In South Tyrol (CHRIS) study, called the CHRIS-NAFLD study. Here, we present the study protocol along with baseline and follow-up characteristics of study participants. METHODS: Among the first 4979 CHRIS study participants, 227 individuals with T2D were identified and recalled, along with 227 age- and sex-matched non-T2D individuals. Participants underwent ultrasound and transient elastography examination to evaluate the presence of hepatic steatosis and liver stiffness. Additionally, sampling of saliva and faeces, biochemical measurements and clinical interviews were carried out. RESULTS: We recruited 173 T2D and 183 non-T2D participants (78% overall response rate). Hepatic steatosis was more common in T2D (63.7%) than non-T2D (36.3%) participants. T2D participants also had higher levels of liver stiffness (median 4.8 kPa, interquartile range (IQR) 3.7, 5.9) than non-T2D participants (median 3.9 kPa, IQR 3.3, 5.1). The non-invasive scoring systems like the NAFLD fibrosis score (NFS) suggests an increased liver fibrosis in T2D (mean − 0.55, standard deviation, SD, 1.30) than non-T2D participants (mean − 1.30, SD, 1.17). DISCUSSION: Given the comprehensive biochemical and clinical characterization of study participants, once the bioinformatics classification of the microbiota will be completed, the CHRIS-NAFLD study will become a useful resource to further our understanding of the relationship between microbiota, T2D and NAFLD. BioMed Central 2019-12-04 /pmc/articles/PMC6891972/ /pubmed/31801616 http://dx.doi.org/10.1186/s12967-019-02130-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Protocol
Motta, Benedetta M.
Grander, Christoph
Gögele, Martin
Foco, Luisa
Vukovic, Vladimir
Melotti, Roberto
Fuchsberger, Christian
De Grandi, Alessandro
Cantaloni, Chiara
Picard, Anne
Mascalzoni, Deborah
Rossini, Alessandra
Pattaro, Cristian
Tilg, Herbert
Pramstaller, Peter P.
Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
title Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
title_full Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
title_fullStr Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
title_full_unstemmed Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
title_short Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
title_sort microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891972/
https://www.ncbi.nlm.nih.gov/pubmed/31801616
http://dx.doi.org/10.1186/s12967-019-02130-z
work_keys_str_mv AT mottabenedettam microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT granderchristoph microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT gogelemartin microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT focoluisa microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT vukovicvladimir microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT melottiroberto microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT fuchsbergerchristian microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT degrandialessandro microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT cantalonichiara microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT picardanne microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT mascalzonideborah microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT rossinialessandra microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT pattarocristian microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT tilgherbert microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy
AT pramstallerpeterp microbiotatype2diabetesandnonalcoholicfattyliverdiseaseprotocolofanobservationalstudy